Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers

Screening for SARS-CoV-2-Infections in Teachers, Childcare Educators, Pupils and Preschoolers in the State of Mecklenburg-Vorpommern

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04619407

Acronym

COKITS

Enrollment

142

Registered

2020-11-06

Start date

2020-11-04

Completion date

2021-03-26

Last updated

2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Keywords

serology, antibody formation, epidemiology

Brief summary

The main objectives of this study are 1. to establish the prevalence of SARS-CoV-2 in schools and kindergartens in the State of Mecklenburg-Vorpommern in autumn and winter 2020/2021 2. to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in teachers and childcare educators over time

Detailed description

Detailed Description: This study aims to collect information on teachers and childcare educators as well as on pupils and preschoolers in the State of Mecklenburg-Vorpommern Over a 5 month period, 5 study visits per participant are planned. At each visit, nasal/throat swabs (for PCR testing) will be collected and participants will be asked to fill in a questionnaire (asking for SARS-CoV-2 risk factors, perceived risk, and impact of the pandemic on their quality of life). In adults, additional blood samples (for SARS-CoV-2 antibody testing) will be collected at the first and the last study visit. This will help to gain a better understanding of viral load and antibody development over time. The remaining blood samples will be stored in a repository for future research. The study is part of a modular SARS-CoV-2-research programme of the University Medicine Greifswald.

Interventions

DIAGNOSTIC_TESTNasopharyngeal swab

SARS-CoV-2 PCR

DIAGNOSTIC_TESTSerum testing

Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

3 Years to 67 Years

Healthy volunteers

Yes

Inclusion criteria

* See cohort descriptions * Willing to have blood samples stored for future research

Exclusion criteria

\- None

Design outcomes

Primary

Measure	Time frame	Description
Share of participants with SARS-CoV-2 detectable in PCR	5 months	Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)

Secondary

Measure	Time frame	Description
Seroprevalence of SARS-CoV-2 antibodies	At study inclusion	Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life	At study inclusion	As assessed by a monthly questionnaire
Share of participants with SARS-CoV-2 detectable in PCR	At study inclusion	Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026